ArticleNucleic acids research2026
NPCDR 2.0: the activity and structure landscape of natural product-based drug combination.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Natural products (NPs) have emerged as the ideal candidates to combine with other therapeutic agents, and the NPCDR has been developed to provide the data on NP-based drug combinations. Recent study increasingly focuses on the exploration of the activity profiles and structural data of such combinations, which were regarded as the cornerstone for a deeper understanding of the therapeutic properties. Here, the NPCDR was thus updated to its 2.0 version by systematically offering the activity profiles and structural data of NP-based drug combinations. Particularly, a total of 3814 activity data were collected for 584 drug combinations, and the structure data of 123 natural products and clinical drugs that interacted with their therapeutic targets were provided, together with binding residues and energies. Moreover, various pharmacological data (such as ADMET properties, drug combination ratios, and interaction patterns between different targets) were provided for NP-based drug combinations. NPCDR 2.0 can now be freely accessed by all users at https://idrblab.org/npcdr/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.